DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer
Cancer · 2025
DOI: 10.1002/cncr.35726 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Sirui Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Mutation, DNA Repair, DNA Damage. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
This study aims to explore the genetic characteristics of biliary tract cancer (BTC), with a particular focus on the impact of DNA damage response and repair (DDR) genes on clinical outcomes.
Methods
A total of 180 patients with BTC and next‐generation sequencing data were retrospectively analyzed. Clinical outcomes were compared between DDR‐positive and DDR‐negative groups.
Results
DDR mutations were found in 28.3% of patients, with ATM (7.8%), BAP1 (5.6%), and BRCA2 (3.3%) being the most common. DDR‐positive patients receiving first‐line platinum‐based chemotherapy ( n = 73) had a significantly higher objective response rate (50.0% vs. 14.9 %; p = .001), longer median progression‐free survival (mPFS) (7.7 vs. 3.8 months; p = .001) and longer median overall survival (28.6 vs. 11.9 months; p < .001). Multivariate analysis confirmed that deleterious DDR gene mutations were independently associated with prolonged mPFS (hazard ratio [HR], 0.37; 95% CI, 0.20–0.67; p < .001) and median overall survival (mOS) (HR, 0.19; 95% CI, 0.08–0.46; p < .001). In 56 patients receiving immunotherapy combined with chemotherapy, DDR‐positive patients had a significantly higher overall response rate (45% vs. 8.3%; p = .001), longer mPFS (7.7 vs. 3.8 months; p = .009), and longer mOS (12.7 vs. 8.8 months; p = .011). Multivariate analysis showed that the presence of deleterious DDR gene mutations was associated with significantly longer mPFS (HR, 0.34; 95% CI, 0.16–0.73); p = .005] and mOS (HR, 0.23; 95% CI, 0.08–0.62; p = .004).
Conclusion
Deleterious DDR gene mutations are associated with improved clinical outcomes in patients with BTC treated with platinum‐based chemotherapy or immunotherapy combined with chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
- Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
ORCID-Profile: Cheng Yi, Hongfeng Gou
Zitieren
APA
Tan, S., Feng, M., Zhou, N., Zhang, S., Yi, C., & Gou, H. (2025). DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. https://doi.org/10.1002/cncr.35726
Vancouver
Tan S, Feng M, Zhou N, Zhang S, Yi C, Gou H. DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. 2025. doi:10.1002/cncr.35726
BibTeX
@article{Tan2025,
author = {Tan, Sirui and Feng, Mingyang and Zhou, Nan and Zhang, Shunyu and Yi, Cheng and Gou, Hongfeng},
title = {DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35726}
}
EUVIMED